173 related articles for article (PubMed ID: 38348622)
21. Lung metastasis and lymph node metastasis are risk factors for hyperprogressive disease in primary liver cancer patients treated with immune checkpoint inhibitors.
Xiao LS; Li QM; Hu CY; Cui H; Hong C; Huang CY; Li RN; Dong ZY; Zhu HB; Liu L
Ann Palliat Med; 2021 Nov; 10(11):11244-11254. PubMed ID: 34670386
[TBL] [Abstract][Full Text] [Related]
22. Current Understanding and Future Perspectives on Hyperprogressive Disease Highlight the Tumor Microenvironment.
Li M; Zhong X; Du F; Wu X; Li M; Chen Y; Zhao Y; Shen J; Yang Z; Xiao Z
J Clin Pharmacol; 2022 Sep; 62(9):1059-1078. PubMed ID: 35303368
[TBL] [Abstract][Full Text] [Related]
23. Hyperprogressive disease in patients with unresectable hepatocellular carcinoma receiving atezolizumab plus bevacizumab therapy.
Maesaka K; Sakamori R; Yamada R; Tahata Y; Imai Y; Ohkawa K; Miyazaki M; Mita E; Ito T; Hagiwara H; Yakushijin T; Kodama T; Hikita H; Tatsumi T; Takehara T
Hepatol Res; 2022 Mar; 52(3):298-307. PubMed ID: 34918428
[TBL] [Abstract][Full Text] [Related]
24. Immune checkpoint inhibitors rechallenge in urological tumors: An extensive review of the literature.
Bimbatti D; Maruzzo M; Pierantoni F; Diminutto A; Dionese M; Deppieri FM; Lai E; Zagonel V; Basso U
Crit Rev Oncol Hematol; 2022 Feb; 170():103579. PubMed ID: 35007699
[TBL] [Abstract][Full Text] [Related]
25. Durable response to combination radiotherapy and immunotherapy in EP-resistant lung large-cell neuroendocrine carcinoma with
Qin Y; Yu M; Zhou L; Jiang L; Huang M
Immunotherapy; 2020 Mar; 12(4):223-227. PubMed ID: 32156177
[TBL] [Abstract][Full Text] [Related]
26. Hyperprogressive disease during atezolizumab plus bevacizumab treatment in patients with advanced hepatocellular carcinoma from Japanese real-world practice.
Yumita S; Ogasawara S; Nakagawa M; Maruta S; Okubo T; Itokawa N; Iino Y; Obu M; Haga Y; Seki A; Kogure T; Ishino T; Ogawa K; Fujiwara K; Iwanaga T; Fujita N; Sakuma T; Kojima R; Kanzaki H; Koroki K; Inoue M; Kobayashi K; Kiyono S; Nakamura M; Kanogawa N; Saito T; Kondo T; Nakagawa R; Nakamoto S; Muroyama R; Chiba T; Itobayashi E; Atsukawa M; Koma Y; Azemoto R; Ito K; Mizumoto H; Kato J; Kato N
BMC Gastroenterol; 2023 Mar; 23(1):101. PubMed ID: 37003980
[TBL] [Abstract][Full Text] [Related]
27. Hyperprogressive disease after immune checkpoint inhibitor therapy in a patient with non‑small cell lung cancer who harbors a TGFBR2 mutation: A case report.
Wang X; Mi X; Li T; Li C
Exp Ther Med; 2023 May; 25(5):228. PubMed ID: 37114179
[TBL] [Abstract][Full Text] [Related]
28. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
29. Disease progression status during initial immune checkpoint inhibitor (ICI) affects the clinical outcome of ICI retreatment in advanced non-small cell lung cancer patients.
Torasawa M; Yoshida T; Takeyasu Y; Shimoda Y; Tateishi A; Matsumoto Y; Masuda K; Shinno Y; Okuma Y; Goto Y; Horinouchi H; Yamamoto N; Takahashi K; Ohe Y
Cancer Med; 2023 Jun; 12(11):12388-12401. PubMed ID: 37062059
[TBL] [Abstract][Full Text] [Related]
30. Hyperprogressive disease during PD-1 blockade in patients with advanced hepatocellular carcinoma.
Kim CG; Kim C; Yoon SE; Kim KH; Choi SJ; Kang B; Kim HR; Park SH; Shin EC; Kim YY; Kim DJ; Chung HC; Chon HJ; Choi HJ; Lim HY
J Hepatol; 2021 Feb; 74(2):350-359. PubMed ID: 32810553
[TBL] [Abstract][Full Text] [Related]
31. Hyperprogressive Disease (HPD) in Solid Tumours Receiving Immune Checkpoint Inhibitors in a Real-World Setting.
Kanjanapan Y; Guduguntla G; Varikara AK; Szajer J; Yip D; Cockburn J; Fadia M
Technol Cancer Res Treat; 2023; 22():15330338231209129. PubMed ID: 37885403
[No Abstract] [Full Text] [Related]
32. Hyperprogressive Disease In a Metastatic Renal Cell Carcinoma Patient After Receiving Immune Checkpoint Inhibitors: A Case Report.
Alkader M; Altaha R; Alkhatib L; Jabali EH; Alsoreeky MS
Cureus; 2022 Oct; 14(10):e30194. PubMed ID: 36381823
[TBL] [Abstract][Full Text] [Related]
33. Hyperprogressive disease after radiotherapy combined with anti-PD-1 therapy in renal cell carcinoma: a case report and review of the literature.
Liu C; Piao J; Shang Z
BMC Urol; 2021 Mar; 21(1):42. PubMed ID: 33743675
[TBL] [Abstract][Full Text] [Related]
34. Hyperprogressive Disease Caused by PD-1 Inhibitors for the Treatment of Pan-Cancer.
Chen S; Gou M; Yan H; Fan M; Pan Y; Fan R; Qian N; Dai G
Dis Markers; 2021; 2021():6639366. PubMed ID: 34239621
[TBL] [Abstract][Full Text] [Related]
35. Outcomes after retreatment with MAPK inhibitors and immune checkpoint inhibitors in melanoma patients.
Persa OD; Mauch C
Future Oncol; 2021 Oct; 17(29):3809-3817. PubMed ID: 34254534
[TBL] [Abstract][Full Text] [Related]
36. Hyperprogressive disease in early-phase immunotherapy trials: Clinical predictors and association with immune-related toxicities.
Kanjanapan Y; Day D; Wang L; Al-Sawaihey H; Abbas E; Namini A; Siu LL; Hansen A; Razak AA; Spreafico A; Leighl N; Joshua AM; Butler MO; Hogg D; Chappell MA; Soultani L; Chow K; Boujos S; Bedard PL
Cancer; 2019 Apr; 125(8):1341-1349. PubMed ID: 30768786
[TBL] [Abstract][Full Text] [Related]
37. Atypical patterns of response and progression in the era of immunotherapy combinations.
Ferrara R; Matos I
Future Oncol; 2020 Aug; 16(23):1707-1713. PubMed ID: 32687405
[TBL] [Abstract][Full Text] [Related]
38. Retreatment With Immune Checkpoint Inhibitors After a Severe Immune-Related Hepatitis: Results From a Prospective Multicenter Study.
Riveiro-Barciela M; Barreira-Díaz A; Callejo-Pérez A; Muñoz-Couselo E; Díaz-Mejía N; Díaz-González Á; Londoño MC; Salcedo MT; Buti M
Clin Gastroenterol Hepatol; 2023 Mar; 21(3):732-740. PubMed ID: 35487453
[TBL] [Abstract][Full Text] [Related]
39. Incidence of immunotherapy-related hyperprogressive disease (HPD) across HPD definitions and cancer types in observational studies: A systematic review and meta-analysis.
Kim MJ; Hong SPD; Park Y; Chae YK
Cancer Med; 2024 Feb; 13(3):e6970. PubMed ID: 38400685
[TBL] [Abstract][Full Text] [Related]
40. Efficacy of Immune Checkpoint Inhibitors in SMARCA4-Deficient Thoracic Tumor.
Shinno Y; Yoshida A; Masuda K; Matsumoto Y; Okuma Y; Yoshida T; Goto Y; Horinouchi H; Yamamoto N; Yatabe Y; Ohe Y
Clin Lung Cancer; 2022 Jul; 23(5):386-392. PubMed ID: 35618627
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
